Acylated glucagon analogue
US11274136B2 · kind B2 · utility
0Cited by
97References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 2019 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | May 13, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.